Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects

Lipids in Health and Disease

Masao Sato²  Bungo Shirouchi²  Ken Kato¹  Yukio Kadooka¹  Akihiro Ogawa¹ 

[1] Milk Science Research Institute, Megmilk Snow Brand Co. Ltd., 1-1-2 Minamidai, Kawagoe, Saitama 350-1165, Japan;Laboratory of Nutrition Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School of Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka 812-8581, Japan

关键词: Triacylglycerol;    Non-esterified fatty acid;    Fermented milk products;    Postprandial lipid response;    Oral fat-loading test;    Lactobacillus gasseri SBT2055;    Probiotics;   

Others  :  811278
DOI  :  10.1186/1476-511X-13-36

 received in 2013-12-02, accepted in 2014-02-05,  发布年份 2014

【 摘 要 】

Background

Lactobacillus gasseri SBT2055 (LG2055) inhibits dietary fat absorption in rats and exerts preventive effects on abdominal adiposity in rats and humans. The present study aimed to evaluate the effects of LG2055 on postprandial serum lipid responses in Japanese subjects with hypertriacylglycerolemia after the intake of oral fat-loading test (OFLT) meals.

Methods

We conducted a single-blind, placebo-controlled, within-subject, repeated-measure intervention trial. Twenty subjects initially ingested the fermented milk (FM) without LG2055 for 4 weeks (control FM period), followed by a 4-week washout period, and then consumed FM containing LG2055 for 4 weeks (active FM period). The subjects were asked to consume FM at 200 g/day. At the end of each 4-week period, an 8-h OFLT was conducted. Blood samples were collected at fasting and every hour for 8 h after OFLT meal intake. Thereafter, postprandial serum non-esterified fatty acid (NEFA) and triacylglycerol (TAG) levels and fasting blood parameters were measured.

Results

The OFLT showed that the postprandial serum NEFA levels from 120 to 480 min and the postprandial serum TAG level at 120 min in the active FM period were significantly (P < 0.05) lower than those in the control FM period. The fasting serum NEFA level in the active FM period significantly (P < 0.001) decreased at week 4 from the initial period compared with the control FM period.

Conclusions

The consumption of probiotic LG2055 reduced postprandial and fasting serum NEFA levels, suggesting its possible contribution to the reduction of the risk for obesity and type 2 diabetes mellitus.

Trial registration

UMIN000011605

【 授权许可】

   
2014 Ogawa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Seto Y, Kimura A, Akai Y, Fujiwara S: Distribution of the Lactobacillus acidophilus complex in human fecal specimens examined by restriction fragment length polymorphism of the 16S rRNA genes. Biosci Microflora 2003, 22:75-83.
• [2]Takahashi H, Fujita T, Suzuki Y, Benno Y: Monitoring and survival of Lactobacillus gasseri SBT2055 in the human intestinal tract. Microbiol Immunol 2006, 50:867-870.
• [3]Fujiwara S, Seto Y, Kimura A, Hashiba H: Establishment of orally-administered Lactobacillus gasseri SBT2055SR in the gastrointestinal tract of humans and its influence on intestinal microflora and metabolism. J Appl Microbiol 2001, 90:343-352.
• [4]Hamad EM, Sato M, Uzu K, Yoshida T, Higashi S, Kawakami H, Kadooka Y, Matsuyama H, Abd El-Gawad IA, Imaizumi K: Milk fermented by Lactobacillus gasseri SBT2055 influences adipocyte size via inhibition of dietary fat absorption in Zucker rats. Br J Nutr 2009, 101:716-724.
• [5]Sato M, Uzu K, Yoshida T, Hamad EM, Kawakami H, Matsuyama H, Abd El-Gawad IA, Imaizumi K: Effects of milk fermented by Lactobacillus gasseri SBT2055 on adipocyte size in rats. Br J Nutr 2008, 99:1013-1017.
• [6]Kadooka Y, Ogawa A, Ikuyama K, Sato M: The probiotic Lactobacillus gasseri SBT2055 inhibits enlargement of visceral adipocytes and upregulation of serum soluble adhesion molecule (sICAM-1) in rats. Int Dairy J 2011, 21:623-627.
• [7]Miyoshi M, Ogawa A, Higurashi S, Kadooka Y: Anti-obesity effect of Lactobacillus gasseri SBT2055 accompanied by inhibition of pro-inflammatory gene expression in the visceral adipose tissue in diet-induced obese mice. Eur J Nutr 2013. e-pub ahead of print 6 August 2013; doi:10.1007/s00394-013-0568-9
• [8]Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M, Tsuchida T: Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr 2010, 64:636-643.
• [9]Kadooka Y, Sato M, Ogawa A, Miyoshi M, Uenishi H, Ogawa H, Ikuyama K, Kagoshima M, Tsuchida T: Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomized controlled trial. Br J Nutr 2013, 110:1696-1703.
• [10]Carrière F, Renou C, Ransac S, Lopez V, De Caro J, Ferrato F, De Caro A, Fleury A, Sanwald-Ducray P, Lengsfeld H, Beglinger C, Hadvary P, Verger R, Laugier R: Inhibition of gastrointestinal lipolysis by orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2001, 281:G16-G28.
• [11]U.S. Food and Drug Administration (fda): Orlistat (Marketed As Alli And Xenical) Information : ; http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm180076.htm webcite] (accessed November 29, 2013
• [12]Tan KC, Tso AW, Tam SC, Pang RW, Lam KS: Acute effect of orlistat on postprandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus. Diabet Med 2002, 19:944-948.
• [13]Kumao T, Fujii S: Mannooligosaccharides blended coffee beverage intake increases the fat level in feces. J Health Sci 2006, 52:329-332.
• [14]Kumao T, Fujii S, Asakawa A, Takehara I, Fukuhara I: Effect of coffee drink containing mannooligosaccharides on total amount of excreted fat in healthy adults. J Health Sci 2006, 52:482-485.
• [15]Asano I, Fujii S, Ozaki K, Takahara I, Yano Y, Fukuhara I: Effects of “coffee beverage” containing mannooligosaccharides from coffee on human abdominal fat by long term ingestion. Jpn J Food Eng 2005, 6:133-141.
• [16]Asano I, Fujii S, Kaneko M, Takehara I, Fukuhara I: Investigation of mannooligosaccharides blended coffee beverage on abdominal fat reduction in human. Jap J Med Pharm Sci 2006, 55:93-103.
• [17]Guericiolini R: Mode of action of orlistat. Int J Obes Relat Metab Disord 1997, 21:S12-S23.
• [18]Lopez S, Bermudez B, Ortega A, Varela LM, Pacheco YM, Villar J, Abia R, Muriana FJ: Effects of meals rich in either monounsaturated or saturated fat on lipid concentrations and on insulin secretion and action in subjects with high fasting triglyceride concentrations. Am J Clin Nutr 2011, 93:494-499.
• [19]National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Panel (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
• [20]Report of a World Health Organization Consultation: Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Diabetes Res Clin Pract 2011, 93:299-309.
• [21]Matsumura A: Inhibitory effects of probiotics on pancreatic lipase [in Japanese]. J Intest Microbiol 2010, 24:287-292.
• [22]Zhou Y, Inoue N, Ozawa R, Maekawa T, Izumo T, Kitagawa Y, Kiso Y, Shibata H, Ikeda I: Effects of heat-killed Lactobacillus pentosus S-PT84 on postprandial hypertriacylglycerolemia in rats. Biosci Biotechnol Biochem 2013, 77:591-594.
• [23]Lambert JE, Parks EJ: Postprandial metabolism of meal triglyceride in humans. Biochim Biophys Acta 1821, 2012:721-726.
• [24]Frayn KN, Coppack SW, Fielding BA, Humphreys SM: Coordinated regulation of hormone-sensitive lipase and lipoprotein lipase in human adipose tissue in vivo: implications for the control of fat storage and fat mobilization. Adv Enzyme Regul 1995, 35:163-178.
• [25]Tan GD, Fielding BA, Currie JM, Humphreys SM, Désage M, Frayn KN, Laville M, Vidal H, Karpe F: The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 2005, 48:83-95.
• [26]Wagstaff AJ, Goa KL: Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002, 62:1805-1837.
• [27]Kim SK, Hur KY, Kim HJ, Shim WS, Ahn CW, Park SW, Cho YW, Lim SK, Lee HC, Cha BS: The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment. Eur J Endocrinol 2007, 157:167-174.
• [28]Maraki MI, Sidossis LS: The latest on the effect of prior exercise on postprandial lipaemia. Sports Med 2013, 43:463-481.
• [29]Friday KE, Srinivasan SR, Elkasabany A, Dong C, Wattigney WA, Dalferes E Jr, Berenson GS: Black-white differences in postprandial triglyceride response and postheparin lipoprotein lipase and hepatic triglyceride lipase among young men. Metabolism 1999, 48:749-754.
• [30]Hara Y, Moriguchi S, Kusumoto A, Nakai M, Ono Y, Abe K, Ohta H, Shibata H, Kiso Y, Egawa K: Suppressive effect of oolong tea polymerized polyphenols-enriched oolong tea on postprandial serum triglyceride elevation [in Japanese]. Jpn Pharmacol Ther 2004, 32:335-342.
• [31]Unno T, Tago M, Suzuki Y, Nozawa A, Sagesaka YM, Kakuda T, Egawa K, Kondo K: Effect of tea catechins on postprandial plasma lipid responses in human subjects. Br J Nutr 2005, 93:543-547.
• [32]Sugiyama H, Akazome Y, Shoji T, Yamaguchi A, Yasue M, Kanda T, Ohtake Y: Oligomeric procyanidins in apple polyphenol are main active components for inhibition of pancreatic lipase and triglyceride absorption. J Agric Food Chem 2007, 55:4604-4609.
• [33]Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
• [34]Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E: A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995, 38:1213-1217.
• [35]Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M: FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab 2002, 283:E12-E19.
• [36]Charles MA, Eschwège E, Thibult N, Claude JR, Warnet JM, Rosselin GE, Girard J, Balkau B: The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 1997, 40:1101-1106.
• [37]Frayn KN, Williams CM, Arner P: Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Clin Sci 1996, 90:243-253.
• [38]Chang BJ, Park SU, Jang YS, Ko SH, Joo NM, Kim SI, Kim CH, Chang DK: Effect of functional yogurt NY-YP901 in improving the trait of metabolic syndrome. Eur J Clin Nutr 2011, 65:1250-1255.